The American generic medicines manufacturer WATSON PHARMACEUTICALS will be paying at least USD 644 million for its competitor SCHEIN PHARMACEUTICALS. WATSON will be offering USD 19.50 for every SCHEIN share, in an attempt to acquire at least 75% in BAYER CORP.